Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods
This work addresses early detection of cardiotoxicity for cancer patients to improve treatment outcomes and quality of life, but it is incremental as it applies existing machine learning methods to a specific clinical dataset.
This study tackled the problem of predicting heart failure risk in cancer patients using historical EHR data, achieving an AUC of 0.9077 with a gradient boosting model. It demonstrated feasibility in identifying at-risk patients, though specificity dropped to 0.7089 in a chemotherapy-exposed subgroup.
Cardiotoxicity related to cancer therapies has become a serious issue, diminishing cancer treatment outcomes and quality of life. Early detection of cancer patients at risk for cardiotoxicity before cardiotoxic treatments and providing preventive measures are potential solutions to improve cancer patients's quality of life. This study focuses on predicting the development of heart failure in cancer patients after cancer diagnoses using historical electronic health record (EHR) data. We examined four machine learning algorithms using 143,199 cancer patients from the University of Florida Health (UF Health) Integrated Data Repository (IDR). We identified a total number of 1,958 qualified cases and matched them to 15,488 controls by gender, age, race, and major cancer type. Two feature encoding strategies were compared to encode variables as machine learning features. The gradient boosting (GB) based model achieved the best AUC score of 0.9077 (with a sensitivity of 0.8520 and a specificity of 0.8138), outperforming other machine learning methods. We also looked into the subgroup of cancer patients with exposure to chemotherapy drugs and observed a lower specificity score (0.7089). The experimental results show that machine learning methods are able to capture clinical factors that are known to be associated with heart failure and that it is feasible to use machine learning methods to identify cancer patients at risk for cancer therapy-related heart failure.